Skip to content
Companies

RenovoRx

Intra-arterial chemotherapy delivery for pancreatic cancer

Raised to date

$10M

of $10M offered across 1 Form D filing

Still open
$71
Investors
16
Last filed
Apr 9, 2026

About

RenovoRx, Inc. is a publicly traded (Nasdaq: RNXT) life sciences company in Mountain View, California developing targeted oncology therapies and commercializing drug-delivery hardware. Its patented Trans-Arterial Micro-Perfusion (TAMP) platform delivers therapeutic agents across the arterial wall near a tumor site rather than systemically. The company sells RenovoCath, an FDA-cleared drug-delivery device for temporary vessel occlusion and chemotherapeutic infusion, and is running the Phase III TIGeR-PaC trial of intra-arterial gemcitabine in locally advanced pancreatic cancer. CEO Shaun Bagai has led the company since 2014.

Delivers chemotherapy directly to the tumor site through the arterial wall instead of intravenously, aiming to improve local drug concentration while reducing the systemic toxicity that limits conventional infusion.

Funding

  • EquityFiled Apr 9, 2026Form D
    $10M/ $10M

Product

RenovoCath

Medical device — drug delivery

An FDA-cleared drug-delivery device for temporary vessel occlusion and infusion of chemotherapeutic agents, used to deliver treatment directly to solid tumors.

  • FDA-cleared and commercially available
  • Temporary vessel occlusion with local drug infusion
  • Built on the Trans-Arterial Micro-Perfusion (TAMP) platform

Built for

Interventional radiologists and oncology centers treating patients with solid tumors, particularly locally advanced pancreatic cancer and sarcoma

People on file